Approx. two thirds of MS patients have Symptomatic Improvements with LDN

[Guest guest]

In addition to the apparent ability of LDN to stop disease progression,

approximately two-thirds of MS patients starting LDN have some symptomatic

improvement generally apparent within the first few days. There are two types of

such improvement:

One is reduction in spasticity when this is present, sometimes allowing easier

ambulation when spasticity in the legs has been a prominent element of a

patient's difficulty in walking or standing. This is unlikely to represent a

direct effect of LDN on the disease process, but rather reduction in the

irritability in nervous tissue surrounding plaques. Endorphins have been shown

to reduce irritability of nervous tissue, e.g., by reducing seizures in patients

with epilepsy.

The other area of symptomatic improvement in some patients is a reduction in

MS-related fatigue. This is, also, not likely due to a direct effect on the MS

disease process, but rather an indirect one caused by restoration of normal

endorphin levels improving energy.

Patients who are in the midst of an acute exacerbation when they start LDN have

generally shown rapid resolution of the attack. In two patients, chronic visual

impairment due to old episodes of optic neuritis has shown fluctuating

improvement.